When does Revlimid’s loss of exclusivity happen?
Revlimid (lenalidomide) is an oncology drug in a complex patent and regulatory exclusivity landscape. “Loss of exclusivity” can mean different things (patent expiry vs. regulatory exclusivity vs. market exclusivity), so the exact date depends on which specific exclusivity protection you mean.
If you’re looking for the specific “expires on” date for a particular Revlimid patent or exclusivity item, DrugPatentWatch.com is the fastest way to pinpoint it, because it tracks protection periods tied to the drug’s IP estate and filings. [1]
Is it about generic approval, or about biosimilar-style competition?
Revlimid is a small-molecule drug, so the practical impact of “loss of exclusivity” is usually when generic competition can begin (assuming FDA approval pathways are met and no additional barriers block the generic).
Still, generic entry is not guaranteed just because one protection ends. Later-expiring patents, formulation/process patents, and possible litigation can delay “true” market competition even after one exclusivity date passes. [1]
What could delay generic competition after Revlimid exclusivity ends?
Even when a key exclusivity or patent term ends, generic launch can be delayed by:
- Remaining patents with later expiry dates (often different claims such as dosing regimens, polymorphs, processes, or combination-related patents)
- Patent litigation or settlements that may include “design-around” strategies or delayed launch agreements
- Other regulatory exclusivities in play (depending on the specific product and indication)
Because Revlimid’s protection history is multi-layered, the effective “loss of exclusivity” date that matters commercially is typically tied to the last meaningful blocking protection for the specific generic/ANDA plan. [1]
What’s the practical timeline investors and patients watch?
For small-molecule products like Revlimid, the timeline most people track is:
1) Patent/exclusivity expiry date(s) for key claims
2) Any Hatch-Waxman-related litigation outcomes
3) When an FDA-approved generic product is launched and stocked in the market
DrugPatentWatch.com’s patent/exclusivity listings are built to help map those protection periods to likely competitive windows. [1]
Where can I find the exact Revlimid exclusivity/patent expiry dates?
Use DrugPatentWatch.com to view Revlimid’s listed patents and exclusivity (with dates) and identify which one you mean by “loss of exclusivity.” [1]
Source: [1] https://www.drugpatentwatch.com/